| Document |
Document Title |
|
WO/2023/109741A1 |
A pharmaceutical composition for preventing and/or treating cancer, comprising a combination of a CDK4/6 inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt thereof and a second therapeutic agent or a phar...
|
|
WO/2023/114428A1 |
The disclosure provides heterocycle derivatives of Formula (I) for the inhibition of the oligosaccharyltransferase complex and the treatment of disease.
|
|
WO/2023/108108A1 |
Described herein are compounds I that are RAF inhibitors and their use in the treatment of disorders such as cancers.
|
|
WO/2023/107938A1 |
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament f...
|
|
WO/2023/107979A1 |
Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise an FGFR kinase inhibitor. Some embodiments comprise combination therapy featuring the FGFR kinase inhibitor with at least one oncology...
|
|
WO/2023/108036A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to sulfur- and selenium-containing compounds that act as agonists and/or antagonists of cannabi...
|
|
WO/2023/104209A1 |
Provided are a class of METTL3 inhibitor compounds and a use thereof in preparation of a medication for inhibiting METTL3, thereby providing a new option for clinically selecting and/or preparing a medication for a disease related to MET...
|
|
WO/2023/104170A1 |
One embodiment of the disclosure is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) can be used to treat polyQ-related neurode...
|
|
WO/2023/107722A1 |
This disclosure provides compounds of formula (I) and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating ...
|
|
WO/2023/102645A1 |
The present invention provides novel crystalline forms of apalutamide. Specific crystalline forms provided by the invention include apalutamide Form APO-I, a cocrystal solvate of apalutamide, vanillin, and n-butyl acetate; apalutamide Fo...
|
|
WO/2023/104107A1 |
Provided are a salt of a compound represented by formula (A), a solid form and a crystal form thereof, a pharmaceutical composition comprising same, the use thereof and a preparation method therefor. Compared with the compound represente...
|
|
WO/2023/107547A2 |
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurolo...
|
|
WO/2023/107863A1 |
Described herein are compounds of Formula I that are inhibitors of wild type and oncogenic mutant c-KIT kinase and their use in the treatment of disorders such as cancers.
|
|
WO/2023/107714A2 |
This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, di...
|
|
WO/2023/105481A1 |
The present invention relates pharmaceutical compositions comprising a solid dispersion. More specifically, the present invention relates to pharmaceutical compositions for the treatment of Hepatitis B Virus (HBV). The present invention ...
|
|
WO/2023/104009A1 |
The present invention relates to a mitochondria-targeted positron emission or fluorescent probe, and a preparation method therefor and the use thereof. The probe has the structure as shown in formula (I), and is a 18F or 19F substituted ...
|
|
WO/2023/107894A1 |
Provided herein is a combination therapy and methods of using such combination therapy to treat diseases or disorders associated with PKC and c-MET.
|
|
WO/2023/105387A1 |
Described herein are compounds of Formula I: I and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R7, RF, t1, Y1, and Y2 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such com...
|
|
WO/2023/108103A1 |
Described herein are compounds (I) that are RAF inhibitors and their use in the treatment of disorders such as cancers.
|
|
WO/2023/104155A1 |
The present disclosure relates to compounds of formula (I) and formula (II), or salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs or polymorphs of said compounds, and the uses of same. The present discl...
|
|
WO/2023/106310A1 |
The present invention pertains to: a compound, or a pharmacologically acceptable salt thereof, having GLP-1 receptor agonist activity and offering utility as an agent for treating or preventing diseases involving GLP-1 receptors; and a p...
|
|
WO/2023/104941A1 |
The invention relates to the field of bioconjugation of functional entities (payloads) to targeting agents, in particular biological targeting agents, such as antibody drug conjugates (ADCs), where one or more payload molecules are conju...
|
|
WO/2023/107630A2 |
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurolo...
|
|
WO/2023/104148A1 |
Disclosed are a compound shown in following general formula I, and a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R1 is preferably a pyridyl group; R2 is preferably a halogen group, and halogenated C1-4 alkoxy ...
|
|
WO/2023/108140A1 |
The present specification provides methods for treating cancers characterized in having an activated hedgehog pathway.
|
|
WO/2023/104882A1 |
The invention provides viral protease inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compou...
|
|
WO/2023/102184A1 |
The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
|
|
WO/2023/102022A1 |
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula (I), tautomers thereof, deuterated derivatives of those compounds or tautomers, and phar...
|
|
WO/2023/102523A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...
|
|
WO/2023/098740A1 |
The present invention belongs to the technical field of photoelectric materials, and particularly relates to an organic room-temperature electrophosphorescent material, and a preparation method therefor and an organic electroluminescent ...
|
|
WO/2023/099354A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein Q, R1, R2 and R4 are as defined herein. The invention further relates to herbicidal compositions which comprise a co...
|
|
WO/2023/102087A1 |
The present disclosure encompasses solid state forms of Tavapadon, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2023/098821A1 |
Provided are a pyrimidine compound, and a preparation method therefor and the use thereof. Specifically, provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. The compound has a new structure, ...
|
|
WO/2023/099381A1 |
The present invention relates to novel herbicidally effective (1,4,5-trisubstituted-1H-pyrazole-3-yl)oxy-2-alkoxy alkyl acids and the derivatives thereof according to general formula (I) and to their agrochemically compatible/acceptable ...
|
|
WO/2023/102529A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...
|
|
WO/2023/102378A1 |
The present invention relates to macrocyclic compounds of any one of Formula (I), or a pharmaceutically acceptable form thereof, pharmaceutical compositions comprising the same, methods of preparing the same, and methods of treating canc...
|
|
WO/2023/098815A1 |
An aromatic compound, a pharmaceutical composition, and an application thereof. Specifically disclosed are the compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate of the pharmaceutically acceptabl...
|
|
WO/2023/102239A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...
|
|
WO/2023/100918A1 |
Provided is a novel dry eye treatment agent that has a strong tear secretion promotion effect. The present invention pertains to: 4-[(3,5-difluorobenzyl)amino]-6-[[3-(piperidine-3-carboxamid
e)phenyl]amino]nicotinamide, a salt thereof,...
|
|
WO/2023/098699A1 |
The present invention provides compounds of Formula (I) which can be used as CD38 inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as...
|
|
WO/2023/097386A1 |
The present invention relates to selective HDAC6-inhibiting N-acylhydrazone compounds. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), and to the methods for producing same, compositions, kit...
|
|
WO/2023/098439A1 |
A pyrazole derivative, and a preparation method therefor and a use thereof in medicine. In particular, the present invention relates to a PRMT5 inhibitor having a structure shown in formula (I), a preparation method therefor, a pharmaceu...
|
|
WO/2023/101326A1 |
The present invention relates to a compound that is an autotaxin (ATX) inhibitor. More specifically, the present invention relates to a novel compound having an inhibitory effect on autotaxin activity, a pharmaceutical composition compri...
|
|
WO/2023/098831A1 |
The present invention relates to a targeted protease degradation (TED) platform. Specifically, disclosed in the present invention is a conjugate of a target molecule-linker-E3 ligase ligand represented by formula Ia or formula Ib, R L-R ...
|
|
WO/2023/096915A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/096854A1 |
Acetylcholine receptor agonist compounds and treatment methods are disclosed. A pharmaceutical composition may include a therapeutically effective amount of an acetylcholine receptor agonist(s) and a pharmaceutically acceptable vehicle. ...
|
|
WO/2023/096850A1 |
The invention provides novel phosphoinositide 3 kinase gamma-selective inhibitors and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, such as solid tumo...
|
|
WO/2023/094830A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R1, R2, R3 and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion ch...
|
|
WO/2023/097221A1 |
Provided herein are heterocyclic derivative compounds and tablet pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as macular degeneration and...
|
|
WO/2023/094833A1 |
The present invention relates to compounds of Formula (I) that target PMS2, a component of DNA Mismatch Repair (MMR) wherein R2, R4, R6, A1, A2, A4, L and Q are each as defined herein. The present invention also relates to processes for ...
|
